<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685110</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1509</org_study_id>
    <nct_id>NCT03685110</nct_id>
  </id_info>
  <brief_title>CoreHip - Post Market Clinical Follow-Up Study</brief_title>
  <official_title>Prospective, Non-Interventional, Multicenter, Post-Market Clinical Follow-up Study CoreHip®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a prospective, non-interventional multicentre cohort study. The
      product under Investigation will be used in Routine clinical practice and according to the
      authorized Instructions for Use (IfU). Aim of this observational study is to collect clinical
      and radiological results of the CoreHip® endoprosthesis system in a Standard Patient
      Population and when used in Routine clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CoreHip® System has a range of different stem designs to address most of the indications
      and anatomical conditions met in Primary THA patients within one implant and Instrument
      System.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Hip Joint Function measured by Harris Hip Score over time (HHS)</measure>
    <time_frame>Preoperative, 3 months postoperative, approx. 12-24 months postoperative and approx. 5 years postoperative</time_frame>
    <description>The Harris Hip Score (HHS) assesses the results of hip surgery, evaluates various hip disabilities and methods of treatment in an adult population. The HHS is a clinician-based outcome measure. The domains covered are pain (pain severity and its effect on activities and need for pain medication), function (daily activities (stair use, using public transportation, sitting, and managing shoes and socks) and gait (limp, support needed, and walking distance)), absence of deformity, and range of Motion (hip flexion, adduction, internal rotation, and extremity length discrepancy).
There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Restoration of preoperative leg length</measure>
    <time_frame>preoperative and 3 months postoperative</time_frame>
    <description>Comparison of preoperative and postoperative leg length</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restoration of preoperative offset</measure>
    <time_frame>preoperative and 3 months postoperative</time_frame>
    <description>Comparison of preoperative and postoperative Offset angle of the femoral neck</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Oxford Hip Score (OHS) over time</measure>
    <time_frame>Preoperative, 3 months postoperative, approx. 12-24 months postoperative and approx. 5 years postoperative</time_frame>
    <description>A patient-reported outcome instrument which contains 12 questions on activities of daily living that assess function and residual pain in patients undergoing total hip replacement (THR) surgery. The score has a maximum of 48 points (best possible outcome), each question has five answers, ranging from 4 Points (best possible) to 0 Points (worst possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Quality of Life (EQ-5D-5L) over time</measure>
    <time_frame>Preoperative, 3 months postoperative, approx. 12-24 months postoperative and approx. 5 years postoperative</time_frame>
    <description>EuroQol five-dimension scale. A standardised instrument created by the EuroQol Group as a measure of health outcome. EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of five Levels reflecting severity (no problems, slight problems, moderate problems, severe problems and extreme Problems). Each answer results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Radiological results: implant position</measure>
    <time_frame>Preoperative, 3 months postoperative, approx. 12-24 months postoperative and approx. 5 years postoperative</time_frame>
    <description>Changes in implant Position throughout the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Radiological results: radiolucent lines</measure>
    <time_frame>Preoperative, 3 months postoperative, approx. 12-24 months postoperative and approx. 5 years postoperative</time_frame>
    <description>Development of radiolucent lines (&quot;Gruen&quot; zones) in AP and lateral x-rays throughout the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to five years</time_frame>
    <description>documentation of all product related adverse Events occuring with the Hip Prosthesis throughout the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Rate of the Hip Prosthesis</measure>
    <time_frame>up to five years</time_frame>
    <description>Survival Analysis of stems in-situ throughout the follow-up period</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Degenerative Osteoarthritis</condition>
  <condition>Rheumatic Arthritis</condition>
  <condition>Fractures, Hip</condition>
  <condition>Necrosis, Femur Head</condition>
  <arm_group>
    <arm_group_label>CoreHip</arm_group_label>
    <description>Clinical and Radiological Data of 300 patients of a Standard Patient Population, who are treated with CoreHip Total Hip Arthroplasty for Indications according to the Instructions for Use (IfU) with a five year follow Up</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CoreHip Total Hip Arthroplasty</intervention_name>
    <description>Replacement of the Hip Joint</description>
    <arm_group_label>CoreHip</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age ≥ 18 years

          -  Indication for THA with a CoreHip® stem

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Patient age &lt; 18 years

          -  Patient not able to regularly participate at the follow-up examinations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Windhagen, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopädische Kliniken im Annastift, Medizinische Hochschule Hannover</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Katrin Wacker</last_name>
    <phone>+49-7461-95-1509</phone>
    <email>anne_katrin.wacker@bbraun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Weiler, Dr.</last_name>
    <phone>+49-7461-95-2721</phone>
    <email>andrea.weiler@aesculap.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ortrhopädische Klinik Markgröningen</name>
      <address>
        <city>Markgröningen</city>
        <state>Baden-Württemberg</state>
        <zip>71706</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Fink, Prof. Dr. med.</last_name>
    </contact>
    <investigator>
      <last_name>Bernd Fink, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopädische Chirurgie München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81369</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Hube, Prof. Dr. med.</last_name>
    </contact>
    <investigator>
      <last_name>Robert Hube, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHH</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Windhagen, Prof. Dr. med.</last_name>
    </contact>
    <investigator>
      <last_name>Henning Windhagen, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thilo Flörkemeyer, PD Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Brig</name>
      <address>
        <city>Brig</city>
        <zip>3902</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Ottersbach, Dr. med.</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Ottersbach, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital Sursee</name>
      <address>
        <city>Sursee</city>
        <zip>6210</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Decking, PD Dr. med.</last_name>
    </contact>
    <investigator>
      <last_name>Jens Decking, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip Arthroplasty</keyword>
  <keyword>Hip Prosthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Femur Head Necrosis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

